Therapeutic protein characterization
24 Nov 2005: Malvern Instruments’ Zetasizer Nano particle characterization system has proved highly effective in studies to compare two forms of a therapeutic antibody – one freshly prepared and the other having undergone a proprietary treatment process. Such studies are important in understanding the characteristics and behaviour of therapeutic preparations, as well as optimizing their formulation and stability.
Malvern Instruments
|
BioInvent and Lund University present data on significant plaque reduction in blood vessels
14 Nov 2005: The results from animal tests on BioInvent International AB’s (SAX:BINV) drug candidate, BI-204, for the treatment of atherosclerosis were presented this weekend at the American Heart Association’s annual medical conference in Dallas.
BioInvent International AB
|
MorphoSys and Wacker Demonstrate High Yield Expression of Antibody Fragments
07 Nov 2005: A feasibility study conducted by Wacker Biotech GmbH on behalf of MorphoSys AG (Frankfurt: MOR; Prime Standard Segment, TecDAX) using Fab fragments, demonstrated that Wacker's E. coli secretion system can offer a far simpler and more cost-effective way of obtaining high yields of antibody fragments, which are used for research, diagnostic and therapeutic applications.
MorphoSys AG
|
ACE BIOSCIENCES AND CRUCELL ENTER RESEARCH AND LICENSING AGREEMENT TO DISCOVER ANTIBODY THERAPIES FOR STREPTOCOCCUS PNEUMONIA
02 Nov 2005: ACE BioSciences A/S, the infectious diseases company and the Dutch biotechnology company Crucell N.V. (Euronext:CRXL and NasdaqNM:CRXL), have entered a research and licensing agreement to discover antibody therapies to combat serious hospital-acquired infections, including those caused by antibiotic-resistant bacteria.
ACE BioSciences
|
Beckman Coulter Introduces New Monoclonal Antibody for Natural Killer (NK) Cell Research
 31 Oct 2005: Beckman Coulter introduces the IOTest® Anti-IRp60-PE monoclonal antibody for the identification of an inhibitory protein present on NK and dendritic cells.
Beckman Coulter
|
MorphoSys Starts Multiple Antibody Programs with Schering AG
10 Oct 2005: MorphoSys AG (Frankfurt Stock Exchange: MOR; Prime Standard Segment, TecDAX) announced today the start of a further three therapeutic antibody programs within the scope of its collaboration with Schering AG, Germany (FSE: SCH; NYSE: SHR).
MorphoSys AG
|
Analysing heart disease with Applied Biosystems' Expression Array System
20 Sep 2005: Researchers at the Leiden/Amsterdam Center for Drug Research (LACDR) are using the Applied Biosystems Expression Array System to identify genes that may predispose towards atherosclerosis.
Applied Biosystems
|
Sigma Introduces New Gene Regulation Antibody Array, Offering Integrated Solutions for Protein Profiling
19 Sep 2005: Sigma, a division of Sigma- Aldrich Corporation, a Science and High Technology company, has launched a new antibody array for identifying Gene Regulation in cell or tissue extracts.
Sigma-Aldrich Corporation
|
MorphoSys Announces Agreement with Japanese Pharmaceutical Company Shionogi
09 Sep 2005: MorphoSys AG and Shionogi & Co., Ltd. have announced that they have signed a three year license agreement on the use of MorphoSys's HuCAL® technology.
MorphoSys AG
|
MorphoSys Starts New Antibody Program With Centocor
07 Sep 2005: MorphoSys AG has announced that with their collaboration with Centocor Inc., a new target molecule involved in immune-mediated and inflammatory diseases has been elected.
MorphoSys AG
|
